Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling

Smith, HL; Willmore, E; Mukhopadhyay, A; Drew, Y; Curtin, NJ

Curtin, NJ (通讯作者)，Newcastle Univ, Fac Med Sci, Ctr Canc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.

CANCERS, 2022; 14 (22):

Abstract

Simple Summary PARPi are approved as monotherapy agents and under advanced clinical investigation as a combination therapy for the treatment of cancer......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索